Skip to main content
Sobi logotype

Main navigation (without target group)

  • About Sobi
    • Who We Are
    • Rare Diseases
    • Responsibility
    • Leadership
  • Our Patients
    • INTO-HLH Registry
    • Our Commitment
    • Patient Advocacy
    • Patient Organizations
    • Patient Support
  • Investigator Sponsored Studies & Grants
  • Careers
  • Contact Us

Breadcrumb

  1. Home
  2. News

News archive

A news archive from Sobi in North America

News archive

A news archive from Sobi in North America

Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout

06/15/2020 - 16:06

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine

05/07/2020 - 08:28

Sobi publishes report for the first quarter 2020

05/05/2020 - 13:24
  • Load More
Smiling woman

Global News

Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine.

More Global News

Filter by Year

2020
2019
2018
2017
2016
2015
2014

Footer Menu

  • Cookies
  • Terms of use

©2022 Sobi, Inc. All rights reserved. PP-11140 (v5.0) 04/22PP-11140 (v5.0) 04/22

This site contains medical information that is intended for residents of the United States and Canada only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy

DOPTELET is a registered trademark of AkaRx, Inc. ©2022 Sobi, Inc. All rights reserved.

DOPTELET CONNECT™ is a trademark of AkaRx, Inc. ©2022 Sobi, Inc. All rights reserved.

GAMIFANT is a registered trademark, owned by Sobi AG and is marketed by Sobi, Inc. ©2022 Swedish Orphan Biovitrum. All rights reserved.

KEPIVANCE is a registered trademark licensed by Sobi, Inc. or its affiliates. ©2022 Sobi Canada, Inc. All rights reserved.

KINERET and KINERET ON TRACK are registered trademarks licensed by Sobi, Inc. or its affiliates. ©2022 Sobi, Inc. All rights reserved.

KINERET and KINERET ON TRACK are registered trademarks licensed by Sobi Canada, Inc. or its affiliates. ©2022 Sobi Canada, Inc. All rights reserved.

ORFADIN is a registered trademark licensed by Sobi, Inc. or its affiliates. ©2022 Sobi, Inc. All rights reserved.

ORFADIN is a registered trademark licensed by Sobi Canada, Inc. or its affiliates. ©2022 Sobi Canada, Inc. All rights reserved.

SYNAGIS® and SYNAGIS CONNECT® are registered trademarks of Arexis AB c/o Swedish Orphan Biovitrum AB (publ) ©2022 Swedish Orphan Biovitrum. All rights reserved.

TEGSEDI® and AKCEA CONNECT® are registered trademarks of Akcea Therapeutics, Inc. Discovered and developed by Ionis Pharmaceuticals and distributed by Sobi, Inc.

TEGSEDI® and AKCEA CONNECT® are registered trademarks of Akcea Therapeutics, Inc. Discovered and developed by Ionis Pharmaceuticals and distributed by Sobi Canada, Inc.

 

 

Please do not modify code below!

Sobi United States
+1 781-786-7364
77 4th Avenue, 3rd Floor
Waltham, MA 02451, USA

Sobi Canada
+1 289-291-3852
1155 North Service Rd. West, Unit #11,
Oakville, Ontario, Canada L6M 3E3

©2022 Sobi, Inc. All rights reserved. PP-11140

This site contains medical information that is intended for residents of the United States and Canada only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy